Skip to main content
SpringerLink
Log in

Delapril/Manidipine

  • Adis Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

▴ Delapril/manidipine 30mg/10mg is a new oral, once-daily, fixed combination of an ACE inhibitor and a dihydropyridine calcium-channel antagonist for the treatment of essential hypertension.

▴ In a dose-finding study in 400 patients with mild to moderate hypertension, delapril/manidipine 30mg/ 10mg once daily produced the greatest reduction in blood pressure (BP) of the combinations tested. Delapril/manidipine 30mg/10mg once daily for 6 weeks reduced systolic BP (SBP)/diastolic BP (DBP)by 15/13mm Hg.

▴ In nonresponders to monotherapy with delapril (n = 155) or manidipine (n = 152), delapril/manidipine 30mg/10mg once daily for 12 weeks reduced mean SBP/DBP by 16/11mm Hg and 16/10mm Hg, respectively.

▴ Delapril/manidipine 30mg/10mg once daily for 12 weeks in patients with mild to moderate hypertension (n = 131) demonstrated significantly greater antihypertensive efficacy than monotherapy with manidipine 10mg once daily (n = 134) or delapril 15mg twice daily (n = 136). Mean SBP/DBP reductions from baseline were 19/14, 15/11 and 14/ 10mm Hg, respectively.

▴ After 50 weeks of therapy with delapril/manidipine 30mg/10mg once daily, mean SBP/DBP was reduced by 22/14mm Hg in patients with mild to moderate hypertension (n = 309).

▴ Delapril/manidipine 30mg/10mg once daily was generally well tolerated. The incidence and nature of adverse events were similar to those observed in recipients of monotherapy with the individual agents. Combination therapy was associated with less ankle oedema than manidipine monotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 2003 May 21; 289(19): 2560–72

    Article  PubMed  CAS  Google Scholar 

  2. Guidelines Committee. 2003 European Society of Hypertension. European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21(6): 1011–53

    Article  Google Scholar 

  3. Guidelines Sub-Committee. 1999 World Health Organization. International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999 Feb; 17(2): 151–83

    Google Scholar 

  4. Gradman AH, Acevedo C. Evolving strategies for the use of combination therapy in hypertension. Current Hypertension Reports 2002; 4: 343–9

    Article  PubMed  Google Scholar 

  5. Taylor AA, Sunthornyothin S. The case for combining angiotensin-converting enzyme inhibitors and calcium-channel blockers. Current Hypertension Reports 1999; 1: 446–53

    Article  PubMed  CAS  Google Scholar 

  6. Razzetti R, Acerbi D. Pharmacokinetic and pharmacologic properties of delapril, a lipophilic nonsulfhydryl angiotensin-converting enzyme inhibitor. Am J Cardiol 1995 Jun 16; 75: 7–12F

    Article  Google Scholar 

  7. Saruta T, Nishikawa K. Characteristics of a new angiotensin converting enzyme inhibitor: delapril. Am J Hypertens 1991 Jan; 4 (1 Pt 2): 23–8S

    CAS  Google Scholar 

  8. Cheer SM, McClellan K. Manidipine: a review of its use in hypertension. Drugs 2001; 61(12): 1777–99

    Article  PubMed  CAS  Google Scholar 

  9. Fogari R, Zoppi A, Mugellini A, et al. Efficacy of delapril in the treatment of mild to moderate essential hypertension: evaluation by 24-hour ambulatory blood pressure monitoring. Adv Ther 1997 Sep; 14: 254–61

    CAS  Google Scholar 

  10. Fogari R, Zoppi A, Corradi L, et al. Effects of different dihydropyridine calcium antagonists on plasma nore-pinephrine in essential hypertension. J Hypertens 2000; 18: 1871–5

    Article  PubMed  CAS  Google Scholar 

  11. Mugellini A, Preti P, Zoppi A, et al. Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus. J Hum Hypertens 2004 Oct; 18(10): 687–91

    Article  PubMed  CAS  Google Scholar 

  12. Rizzoni D, Bevilacqua M, Gobbato C, et al. Blood pressure lowering effects of delapril and manidipine, in hypertensive patients with type 2 diabetes, not adequately controlled by monotherapy [abstract no. 8.6]. High Blood Press Cardiovasc Prev 2005; 12(3): 180

    Article  Google Scholar 

  13. Onoyama K, Nanishi F, Okuda S, et al. Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (delapril) in patients with deteriorated kidney function and in normal control subjects. Clin Pharmacol Ther 1988 Mar; 43(3): 242–9

    Article  PubMed  CAS  Google Scholar 

  14. Salvetti A. Newer ACE inhibitors: a look at the future. Drugs 1990 Dec; 40(6): 800–28

    Article  PubMed  CAS  Google Scholar 

  15. Singlas E, Fillastre JP. Pharmacokinetics of newer drugs in patients with renal impairment (part II). Clin Pharmacokinet 1991 May; 20(5): 389–410

    Article  PubMed  CAS  Google Scholar 

  16. Kelly JG, O’Malley K. Clinical pharmacokinetics of the newer ACE inhibitors: a review. Clin Pharmacokinet 1990 Sep; 19: 177–96

    Article  PubMed  CAS  Google Scholar 

  17. Chiesi Farmaceutici S.p.A. Summary of product characteristics (Iperten 10mg and 20mg tablets). 2006

  18. Morimoto S, Matsumura Y. Manidipine hydrochloride [CV-4093 (2HC1)]. Cardiovasc Drug Rev 1991; 9(3): 207–22

    Article  CAS  Google Scholar 

  19. Deroubaix X, Lins RL, Lens S, et al. Single dose pharmacokinetics of manidipine in hepatic impaired patients and healthy controls. Int J Clin Pharmacol Ther 1998; 36(7): 386–91

    PubMed  CAS  Google Scholar 

  20. Stockis A, Gengler C, Goethals F, et al. Single oral dose pharmacokinetic interaction study of manidipine and delapril in healthy volunteers. Arzneimittelforschung 2003; 53(9): 627–34

    PubMed  CAS  Google Scholar 

  21. Stockis A, De Bruyn S, Gengler C. Pharmacokinetics and tolerability of a new manidipine and delapril fixed oral combination in young and elderly subjects. Arzneimittelforschung 2003; 53(8): 554–61

    PubMed  CAS  Google Scholar 

  22. Zoppi A, Mugellini A, Preti P, et al. Effects of the fixed combination of manidipine plus delapril in the treatment of hypertension inadequately controlled by monotherapy with either component: a phase III, multicenter, open-label, clinical trial. Curr Ther Res 2003 Jul; 64(7): 422–33

    Article  CAS  Google Scholar 

  23. Karpati P, Alberici M, Tocci G, et al. Long-term tolerability and efficacy of the fixed combination of manidipine and delapril in patients with essential hypertension. High Blood Press Cardiovasc Prev 2003; 10(2): 81–6

    Article  Google Scholar 

  24. Mugellini A, Vaccarella A, Celentano A, et al. Fixed combination of manidipine and delapril in the treatment of mild to moderate essential hypertension: evaluation by 24-hour ambulatory blood pressure monitoring. Blood Press 2005 Jul 1; 14 Suppl. 1: 6–13

    Article  Google Scholar 

  25. Mugellini A, Dobovisek J, Planinc D, et al. Efficacy and safety of delapril plus manidipine compared with enalapril plus hydrochlorothiazide in mild to moderate essential hypertension: results of a randomized trial. Clin Ther 2004 Sep; 26(9): 1419–26

    Article  PubMed  CAS  Google Scholar 

  26. Bacchelli S, Degli Esposti D, Alberici M, et al. Effects of the combination of different doses of manidipine and delapril in hypertensive patients [abstract no. P-35]. Am J Hypertens 2002 Apr; 15 (4 Pt 2): 45–46A

    Article  Google Scholar 

  27. Ambrosioni E. Clinical evaluation of manidipine-delapril combination on efficacy and tolerability in hypertensive patients [oral presentation]. New therapeutic approach for hypertension control: the rationale for the ACE inhibitor — calcium channel blocker combination (satellite symposium of the 11 th European Meeting on Hypertension); 2001 Jun 15–19; Milan

  28. Ambrosioni E. Manidipine and delapril in the management of hypertension. Use of a factorial design to evaluate the effects of different combinations of doses in a multicentre, controlled, randomised, double-blind clinical trial for the evaluation of the antihypertensive effect and tolerability of extemporaneous associations. (Data on file). Chiesi Farmaceutici S.p.A., 1998

  29. Zannad F. Multicentre, randomised, parallel group, double-blind, double-dummy, phase III study to compare the antihypertensive effects and tolerability of delapril and manidipine monotherapy to delapril plus manidipine (CHF 1521 fixed combination) in patients with mild to moderate essential hypertension. (Data on file). Chiesi Farmaceutici S.p.A., 2004

  30. Chiesi Farmaceutici S.p.A. Summary of product characteristics (Delaket 15mg and 30mg tablets). 2005

  31. Fogari R, Malamani G, Derosa G, et al. Effect of delapril addition to manidipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients [abstract no. P-205]. Am J Hypertens 2003 May; 16 (5 Pt 2): 113A

    Article  Google Scholar 

  32. Chiesi Farmaceutici S.p.A. Summary of product characteristics (Vivace 30mg + 10mg tablets). 2006

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 1311, New Zealand

    Paul L. McCormack & Gillian M. Keating

Authors
  1. Paul L. McCormack
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul L. McCormack.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McCormack, P.L., Keating, G.M. Delapril/Manidipine. Drugs 66, 961–969 (2006). https://doi.org/10.2165/00003495-200666070-00014

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200666070-00014

Keywords

Search

Navigation